Biopharma financings from January through October 2025 totaled $61.45 billion, roughly in line with the $61.04 billion raised ...

Aussie radiopharma company Advancell Co. Ltd. unveiled promising early clinical data that could redefine how advanced ...

Antibody-drug conjugates (ADCs) carrying topoisomerase I (TOP1) inhibitors, such as trastuzumab deruxtecan (T-DXd), have ...

Phase II data being presented at the American Association for the Study of Liver Diseases annual meeting indicate drug ...

Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody, mezagitamab (TAK-079), sustained kidney function up to 18 months after ...

Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated ...

San Francisco Bay Area researchers from UC Berkeley, UC San Francisco and Stanford University have combined their ...

UNESCO has adopted the first set of global standards on the ethics of neurotechnology amid the rapid advancement in the ...

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the ...

Neok Bio Inc. was formed earlier this year and is already on schedule to file an IND in a few months for its two bispecific ...

Researchers at Crossbridge Bio Inc. have conducted preclinical evaluation of CBB-120, a novel TROP2-directed dual-payload ADC ...

Zhongshan Innovation New Drug Development Co. Ltd. has described conjugates comprising a chelating ligand moiety, a fibroblast activation protein α (FAP) ligand and integrin αvβ3 or integrin αvβ6 ...